MetaADEDB 2.0 @ LMMD
Ethacrynic Acid
(AVOLMBLBETYQHX-UHFFFAOYSA-N)
Structure
SMILES
CCC(=C)C(=O)c1ccc(c(c1Cl)Cl)OCC(=O)O
Type(s)
Approved; Investigational
ATC code(s)
C03CC01
Molecular Formula:
C13H12Cl2O4
Molecular Weight:
303.138
Log P:
3.6057
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
1
TPSA:
63.6
CAS Number(s):
58-54-8
Synonym(s)
1.
Ethacrynic Acid
2.
Edecrin
3.
Etacrynic Acid
4.
Ethacrinic Acid
5.
Ethacrynate Sodium
6.
Ethacrynic Acid, Sodium Salt
7.
Hydromedin
8.
Acid, Etacrynic
9.
Acid, Ethacrinic
10.
Acid, Ethacrynic
11.
Sodium, Ethacrynate
External Link(s)
MeSHD004976
PubChem Compound3278
BindingDB50186231
ChEBI4876
CHEMBLCHEMBL456
DrugBankDB00903
DrugCentral1071
IUPHAR/BPS Guide to PHARMACOLOGY7179
KEGGdr:D00313
Therapeutic Target DatabaseD06TNL
ZINC1382
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AstheniaFAERS: 2US FAERS
2Drug ineffectiveFAERS: 2US FAERS
3VomitingFAERS: 2
Canada Vigilance: 2
Canada Vigilance
US FAERS
4Abdominal discomfortFAERS: 1US FAERS
5Acute kidney injuryFAERS: 15695673
8150749
CTD
US FAERS
6ArthropathyFAERS: 1US FAERS
7Blood creatinine increasedFAERS: 1US FAERS
8Deafness NeurosensoryFAERS: 1US FAERS
9Deafness PermanentFAERS: 1US FAERS
10DeafnessFAERS: 1
Canada Vigilance: 1

View details

CTD
Canada Vigilance
US FAERS
11Drug ToleranceFAERS: 1US FAERS
12Drug dose omissionFAERS: 1US FAERS
13Gastric ulcerFAERS: 1US FAERS
14General physical health deteriorationFAERS: 1US FAERS
15HeadacheFAERS: 1US FAERS
16HypersensitivityFAERS: 1US FAERS
17InflammationFAERS: 1US FAERS
18Joint swellingFAERS: 1US FAERS
19NauseaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
20OliguriaFAERS: 1US FAERS
21OtotoxicityFAERS: 1US FAERS
22Peripheral swellingFAERS: 1US FAERS
23PneumoniaFAERS: 1US FAERS
24Quality of life decreasedFAERS: 1US FAERS
25Sinus headacheFAERS: 1US FAERS
26Visual ImpairmentFAERS: 1US FAERS
27Weight decreasedFAERS: 1US FAERS
28nervous system disorderFAERS: 1US FAERS
29Abdominal Pain4755205CTD
30AgranulocytosisCanada Vigilance: 1Canada Vigilance
31AlkalosisCanada Vigilance: 1Canada Vigilance
32Anorexia5643946CTD
33Dehydration5643946CTD
34GastroenteritisCanada Vigilance: 1Canada Vigilance
35Hearing Loss, Bilateral8294265CTD
36Hearing Loss5754935
8150749
8647736
CTD
37Hypokalemia5090186CTD
38Hyponatremia5090186CTD
39Hypotension19576883CTD
40Necrosis19135076CTD
41PancreatitisCanada Vigilance: 1Canada Vigilance
42Proteinuria6707927CTD
43PurpuraCanada Vigilance: 1Canada Vigilance
44Renal Insufficiency4178003CTD
45Seizures

View details

CTD
46Status Epilepticus2806362CTD
47TinnitusCanada Vigilance: 1Canada Vigilance
48Tremor5643946CTD
49UrticariaCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.